Submitted by Anonymous (not verified) on 6 March 2026 - 15:08
Opinion/decision on a Paediatric investigation plan (PIP): Xeljanz, tofacitinib, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Musculoskeletal and connective tissue disorders, PIP number: EMA/PE/0000222532
Source: